MyFinsight
Home
Blog
About
Contact
Download
Download image
Total comprehensive
loss for the year, net...
-$203,493,000
Unrealized gain on
available-for-sale securities, net...
$326,000
Loss for the year
-$203,819,000
Loss before tax
-$203,819,000
Interest income
$27,592,000
License revenue
attributed from r&d...
$22,123,000
Supply revenue
$380,000
Foreign exchange
gains/(losses)
$13,055,000
Fair value change -
earnout
-$3,992,000
Operating loss
-$225,683,000
Revenue
$22,503,000
Fair value change -
warrants
$22,775,000
Total operating
expenses
$248,186,000
Research and development
expenses
$141,832,000
Selling, general and
administrative expenses
$106,354,000
Back
Back
Income Statement
source: myfinsight.com
NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)